In 2025, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (hereinafter referred to as "the Company") recognizes the importance of collective efforts under the framework of the Company Law of the People's Republic of China and the Articles of Association of the Company. This report summarizes the key work of the Company in 2022 and outlines the main work plan for 2025 as follows:
I. 2025 Company Overall Business Situation
During the reporting period, the Company achieved operating revenue of 3,328,215.94 thousand yuan, a year-on-year decrease of 9.38%. The net profit attributable to shareholders of the Company was 845,147.14 thousand yuan, a year-on-year decrease of 28.01%. The net profit attributable to shareholders of the Company’s stock was 813,577.54 thousand yuan, a year-on-year decrease of 20.28%.
In the international market, the Company achieved operating revenue of 1,765,037.52 thousand yuan, an increase of 7.40% year-on-year. The service revenue accounted for 53% of the total revenue. The Company continues to expand its international business, with a focus on enhancing its market presence in various regions. In 2024, the Company plans to increase its international business revenue by 17%.